Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Acalabrutinib

FDA-approved product (capsule, oral), marketed as Calquence.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Acalabrutinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Chronic lymphocytic leukemia
  • Mantle cell lymphoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bruton's tyrosine kinase (btk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli38.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Acalabrutinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Acalabrutinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    NCT07582159 · start 2026-12-19

    Registered record
    Registry ID
    NCT07582159
    Conditions
    Chronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Small Lymphocytic Lymphoma
    Interventions
    Acalabrutinib; Biospecimen Collection; Bone Marrow Biopsy; Computed Tomography; Positron Emission Tomography; Tafasitamab; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-12-19
    Completion
    2029-04-14
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Small Lymphocytic Lymphoma
    InterventionAcalabrutinib; Biospecimen Collection; Bone Marrow Biopsy; Computed Tomography +3 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

    NCT07024706 · start 2026-06-04

    Registered record
    Registry ID
    NCT07024706
    Conditions
    Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)
    Interventions
    Acalabrutinib; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-06-04
    Completion
    2033-03-23
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)
    InterventionAcalabrutinib; Venetoclax
    PhasePhase 2
    Registry statusRecruiting

  • A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

    NCT07277231 · start 2026-01-22

    Registered record
    Registry ID
    NCT07277231
    Conditions
    Chronic Lymphocytic Leukemia
    Interventions
    Sonrotoclax; Zanubrutinib; Acalabrutinib; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-01-22
    Completion
    2031-11
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia
    InterventionSonrotoclax; Zanubrutinib; Acalabrutinib; Venetoclax
    PhasePhase 3
    Registry statusRecruiting

  • Zanubrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies

    NCT07283965 · start 2025-12-22

    Registered record
    Registry ID
    NCT07283965
    Conditions
    Chronic B-cell Malignancies; BTK Inhibitors; Cardiovascular Diseases
    Interventions
    Zanubrutinib; Acalabrutinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-12-22
    Completion
    2026-03-31
    Enrolment
    15,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic B-cell Malignancies; BTK Inhibitors; Cardiovascular Diseases
    InterventionZanubrutinib; Acalabrutinib
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Mosunetuzumab for CLL MRD Clearance

    NCT07052695 · start 2025-11-24

    Registered record
    Registry ID
    NCT07052695
    Conditions
    Leukemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Lymphoma
    Interventions
    Mosunetuzumab; Ibrutinib; Acalabrutinib; Zanubrutinib; Pirtobrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2025-11-24
    Completion
    2032-12-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Lymphoma
    InterventionMosunetuzumab; Ibrutinib; Acalabrutinib; Zanubrutinib +1 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)

    NCT07021495 · start 2025-07-29

    Registered record
    Registry ID
    NCT07021495
    Conditions
    Chronic Spontaneous Urticaria (CSU); Hidradenitis Suppurativa (HS); Psoriasis (PsO); Atopic Dermatitis (AD); CTCL/ Mycosis Fungoides
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-07-29
    Completion
    2029-12-31
    Enrolment
    840

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Spontaneous Urticaria (CSU); Hidradenitis Suppurativa (HS); Psoriasis (PsO); Atopic Dermatitis (AD) +1 more
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

    NCT06564038 · start 2025-01-30

    Registered record
    Registry ID
    NCT06564038
    Conditions
    Chronic Lymphocytic Leukaemia; Small Lymphocytic Lymphoma; Mantle-cell Lymphoma; Large B-cell Lymphoma; B-cell Non-Hodgkin Lymphoma
    Interventions
    Surovatamig; Prednisone (or equivalent); Rituximab; Cyclophosphamide; Vincristine; Doxorubicin; Acalabrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2025-01-30
    Completion
    2029-06-11
    Enrolment
    408

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukaemia; Small Lymphocytic Lymphoma; Mantle-cell Lymphoma; Large B-cell Lymphoma +1 more
    InterventionSurovatamig; Prednisone (or equivalent); Rituximab; Cyclophosphamide +3 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

    NCT06441097 · start 2024-12-31

    Registered record
    Registry ID
    NCT06441097
    Conditions
    Diffuse Large B-Cell Lymphoma
    Interventions
    Polatuzumab vedotin; Rituximab; Cyclophosphamide; Doxorubicin; Prednisone; Acalabrutinib; Lenalidomide; Decitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2024-12-31
    Completion
    2027-12-31
    Enrolment
    152

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiffuse Large B-Cell Lymphoma
    InterventionPolatuzumab vedotin; Rituximab; Cyclophosphamide; Doxorubicin +4 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period

    NCT06524375 · start 2024-08-09

    Registered record
    Registry ID
    NCT06524375
    Conditions
    Chronic Lymphocytic Leukemia
    Interventions
    Venetoclax; cBTKi Monotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2024-08-09
    Completion
    2030-01-31
    Enrolment
    118

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia
    InterventionVenetoclax; cBTKi Monotherapy
    PhasePhase 2
    Registry statusActive not recruiting

  • Ibrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies

    NCT06561243 · start 2024-07-25

    Registered record
    Registry ID
    NCT06561243
    Conditions
    Chronic B-cell Malignancies; BTK Inhibitors; Cardiovascular Diseases
    Interventions
    BTK inhibitor (Ibrutinib or Acalabrutinib)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2024-07-25
    Completion
    2024-10-30
    Enrolment
    15,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic B-cell Malignancies; BTK Inhibitors; Cardiovascular Diseases
    InterventionBTK inhibitor (Ibrutinib or Acalabrutinib)
    PhaseNot recorded
    Registry statusUnknown

  • Real-world Study of Acalabrutinib

    NCT06767891 · start 2024-07-02

    Registered record
    Registry ID
    NCT06767891
    Conditions
    Mantle Cell Lymphoma (MCL); Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Enrolling by invitation
    Start
    2024-07-02
    Completion
    2029-11
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMantle Cell Lymphoma (MCL); Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    InterventionNot recorded
    PhaseNot recorded
    Registry statusEnrolling by invitation

  • A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL

    NCT05950997 · start 2024-04-16

    Registered record
    Registry ID
    NCT05950997
    Conditions
    Chronic Lymphocytic Leukemia
    Interventions
    Acalabrutinib; Obinutuzumab
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-04-16
    Completion
    2026-09-30
    Enrolment
    89

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia
    InterventionAcalabrutinib; Obinutuzumab
    PhaseNot applicable
    Registry statusRecruiting

  • A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma

    NCT05951959 · start 2023-12-13

    Registered record
    Registry ID
    NCT05951959
    Conditions
    Mantle Cell Lymphoma (MCL)
    Interventions
    Acalabrutinib; Venetoclax; Rituximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-12-13
    Completion
    2028-10-31
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMantle Cell Lymphoma (MCL)
    InterventionAcalabrutinib; Venetoclax; Rituximab
    PhasePhase 2
    Registry statusActive not recruiting

  • Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma

    NCT05820841 · start 2023-06-07

    Registered record
    Registry ID
    NCT05820841
    Conditions
    Large B-cell Lymphoma; Diffuse Large B Cell Lymphoma
    Interventions
    R-miniCHOP + Acalabrutinib; R-miniCHOP
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-06-07
    Completion
    2029-02
    Enrolment
    330

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLarge B-cell Lymphoma; Diffuse Large B Cell Lymphoma
    InterventionR-miniCHOP + Acalabrutinib; R-miniCHOP
    PhasePhase 3
    Registry statusRecruiting

  • Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

    NCT05583149 · start 2023-03-01

    Registered record
    Registry ID
    NCT05583149
    Conditions
    Refractory Aggressive B-cell Lymphomas; Refractory B-Cell Non-Hodgkin Lymphoma; Aggressive B-cell NHL; Diffuse Large B-cell Lymphoma (DLBCL); De Novo or Transformed Indolent B-cell Lymphoma; DLBCL, Nos Genetic Subtypes; T Cell/Histiocyte-rich Large B-cell Lymphoma; EBV-Positive DLBCL, Nos; Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL); High-Grade B-Cell Lymphoma, Nos; C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma; Grade 3b Follicular Lymphoma; C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
    Interventions
    ACALABRUTINIB; LISOCABTAGENE MARALEUCEL; Lymphodepleting chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-03-01
    Completion
    2029-03-01
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRefractory Aggressive B-cell Lymphomas; Refractory B-Cell Non-Hodgkin Lymphoma; Aggressive B-cell NHL; Diffuse Large B-cell Lymphoma (DLBCL) +9 more
    InterventionACALABRUTINIB; LISOCABTAGENE MARALEUCEL; Lymphodepleting chemotherapy
    PhasePhase 2
    Registry statusActive not recruiting